1. Home
  2. PGY vs ABUS Comparison

PGY vs ABUS Comparison

Compare PGY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$12.41

Market Cap

1.0B

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$3.95

Market Cap

888.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PGY
ABUS
Founded
2016
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
888.5M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PGY
ABUS
Price
$12.41
$3.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
1
Target Price
$34.50
$5.00
AVG Volume (30 Days)
5.5M
2.1M
Earning Date
02-09-2026
03-26-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.93
N/A
Revenue
$1,301,360,000.00
$14,606,000.00
Revenue This Year
$18.57
$125.30
Revenue Next Year
$14.58
N/A
P/E Ratio
$13.37
N/A
Revenue Growth
26.07
116.64
52 Week Low
$8.50
$2.71
52 Week High
$44.99
$5.10

Technical Indicators

Market Signals
Indicator
PGY
ABUS
Relative Strength Index (RSI) 24.69 44.23
Support Level $12.05 $3.85
Resistance Level $15.51 $4.26
Average True Range (ATR) 1.34 0.30
MACD -0.72 0.01
Stochastic Oscillator 4.03 46.82

Price Performance

Historical Comparison
PGY
ABUS

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a financial technology company working to reshape the lending marketplace by using machine learning, data analytics, and sophisticated AI-driven credit and analysis technology. It was built to provide a comprehensive solution to enable the credit industry to deliver customers a positive experience while simultaneously enhancing the broader credit ecosystem. Its proprietary API seamlessly integrates into its next-gen infrastructure network of partners to deliver a premium customer user experience and greater access to credit. The company generates majority of its revenue from United States.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: